Psychedelics are Bringing a new wind to the Pharmacopoeia
Neuroscience and Neurological Surgery February 27, 2025 DOI: 10.31579/2578-8868/360 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractHundreds of clinical trials worldwide are testing hallucinogenic substances—psilocybin, LSD, DMT, mescaline, MDMA, and ketamine—for their ability to restore mental health. Psilocybin is the active ingredient in hallucinogenic mushrooms, LSD derives from ergot compounds, DMT is part of ayahuasca, mescaline comes from peyote, and MDMA is an amphetamine known as ecstasy.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Pharmacopoeia Geography |
| Key finding | Several hundred clinical trials are testing hallucinogenic substances for their ability to restore mental health. |
Abstract
Hallucinogenic substances such as psilocybin, LSD or ecstasy are now the subject of several hundred clinical trials around the world to test their ability to restore our mental health. Psilocybin (active ingredient in hallucinogenic mushrooms), LSD (derived from compounds from ergot), dimethyltryptamine (or DMT, part of the composition of ayahuasca), mescaline (derived from peyote), but also MDMA ( amphetamine better known under the name ecstasy) or even ketamine.